Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.

doi:10.2353/jmoldx.2008.070125

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.

The Journal of molecular diagnostics : JMD - 1 Mar 2008

Pinter Ferenc, Papay Judit, Almasi Andrea, Sapi Zoltan, Szabo Edit, Kanya Melinda, Tamasi Anna, Jori Balazs, Varkondi Edit, Moldvay Judit, Szondy Klara, Keri Gyorgy, Dominici Massimo, Conte Pierfranco, Eckhardt Sandor, Kopper Laszlo, Schwab Richard, Petak Istvan

Abstract excerpt

The purpose of this study was to investigate whether detectable protein biomarker overexpression is a prerequisite for the presence of increased gene copy number or activating mutations and responsiveness to the epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib in patients with lung adenocarcinomas. EGFR status was prospectively analyzed in tumor biopsy samples by three methods: protein...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Enzyme Inhibitors

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Gene Dosage

Share to In Situ Hybridization, Fluorescence

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 18258923
DOI: 10.2353/jmoldx.2008.070125
PMCID: PMC2259471

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.PMID 18258923Read ↗

Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerSemantic proximity Read ↗

Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on PrognosisSemantic proximity Read ↗

An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.Semantic proximity Read ↗

Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma.Semantic proximity Read ↗

Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group StudySemantic proximity Read ↗

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.Semantic proximity Read ↗

Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers.Semantic proximity Read ↗

Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay.Semantic proximity Read ↗

High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR.Semantic proximity Read ↗

Increased<i>HER2</i>Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer PatientsSemantic proximity Read ↗

Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.